CHINA PHARMA HOLDINGS, INC. Operating Lease, Payments
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Operating Lease, Payments of $18.83 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-05-15
- CHINA PHARMA HOLDINGS, INC. operating lease, payments for the quarter ending 2026-03-31 was $18.83K, a 5.35% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. operating lease, payments for the quarter ending 2025-12-31 was $19.68K.
- CHINA PHARMA HOLDINGS, INC. operating lease, payments for the quarter ending 2025-09-30 was $19.12K, a 9.22% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. operating lease, payments for the quarter ending 2025-06-30 was $20.01K, a 0.64% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. operating lease, payments for fiscal 2025 was $78.70K, a 28.74% increase from fiscal 2024.
- CHINA PHARMA HOLDINGS, INC. operating lease, payments for fiscal 2024 was $61.13K, a 203.52% increase from fiscal 2023.
- CHINA PHARMA HOLDINGS, INC. operating lease, payments for fiscal 2023 was $20.14K, a 75.44% decline from fiscal 2022.
- CHINA PHARMA HOLDINGS, INC. operating lease, payments for fiscal 2022 was $82.02K.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 9 month as first filed | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | $18.83K 10-Q · filed 2026-05-15 | $38.51K derived: sum of 2 quarters · filed 2026-05-15 | $57.63K derived: sum of 3 quarters · filed 2026-05-15 | $77.64K derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2025-12-31 | $19.68K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $38.80K derived: sum of 2 quarters · filed 2026-04-01 | $58.81K derived: sum of 3 quarters · filed 2026-04-01 | $78.70K 10-K · filed 2026-04-01 | |||
| 2025-09-30 | $19.12K 10-Q · filed 2025-11-12 | $39.13K derived: sum of 2 quarters · filed 2025-11-12 | $59.02K 10-Q · filed 2025-11-12 | $59.03K derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2025-06-30 | $20.01K 10-Q · filed 2025-08-14 | $39.91K 10-Q · filed 2025-08-14 | $39.91K derived: sum of 3 quarters · filed 2026-05-15 | $60.97K derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2025-03-31 | $19.89K 10-Q · filed 2026-05-15 | $19.89K derived: sum of 2 quarters · filed 2026-05-15 | $40.95K derived: sum of 3 quarters · filed 2026-05-15 | $61.10K derived: sum of 4 quarters · filed 2026-05-15 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $21.06K derived: sum of 2 quarters · filed 2026-04-01 | $41.20K derived: sum of 3 quarters · filed 2026-04-01 | $61.13K 10-K · filed 2026-04-01 | $79.46K 10-K · filed 2025-03-31 | ||
| 2024-09-30 | $21.06K 10-Q · filed 2025-11-12 | $41.20K derived: sum of 2 quarters · filed 2025-11-12 | $61.13K 10-Q · filed 2025-11-12 | $24.44K derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $20.14K 10-Q · filed 2025-08-14 | $19.95K 10-Q · filed 2024-08-14 | $40.07K 10-Q · filed 2025-08-14 | $3.38K derived: sum of 3 quarters · filed 2025-08-14 | $23.52K derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | $20.14K 10-Q · filed 2025-05-14 | -$16.76K derived: sum of 2 quarters · filed 2025-05-14 | $3.38K derived: sum of 3 quarters · filed 2025-05-14 | $22.12K derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$36.91K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$16.76K derived: sum of 2 quarters · filed 2025-03-31 | $1.98K derived: sum of 3 quarters · filed 2025-03-31 | $20.14K 10-K · filed 2025-03-31 | $80.65K 10-K · filed 2024-04-01 | ||
| 2023-09-30 | $20.14K 10-Q · filed 2024-11-13 | $38.89K derived: sum of 2 quarters · filed 2024-11-13 | $57.05K 10-Q · filed 2024-11-13 | $59.67K 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $18.74K 10-Q · filed 2024-08-14 | $39.52K 10-Q · filed 2024-08-14 | |||||
| 2022-12-31 | $39.46K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $59.52K derived: sum of 2 quarters · filed 2024-04-01 | $82.02K 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | $20.06K 10-Q · filed 2023-11-13 | $42.55K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |